A recent study introduces a peptide PROTAC specifically designed to target and degrade the cysteine-histidine-rich 1 (CH1) domain of p300, a vital co-activator involved in oncogenic signaling pathways, particularly in PCa (Zhang et al., 2024). The gene discussed is EP300; the disease is posterior cortical atrophy.